Moomoo AI 已提取核心信息
On January 26, 2024, Cardio Diagnostics Holdings, Inc. entered into a Sales Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell up to $17 million in shares of its common stock at its discretion. The sales will be conducted as an 'at the market' offering under the company's effective Registration Statement, which was declared effective by the SEC on February 1, 2024. The company has the flexibility to determine the parameters of the share sales, including the number, timing, and minimum price of shares to be sold. Cardio Diagnostics Holdings will pay Craig-Hallum a 2.5% commission on the gross proceeds from the sales and will cover certain legal costs associated with the agreement. The offering will end when the total sales reach $17 million or upon termination of the Sales Agreement by either party. The net proceeds are intended for general corporate purposes. The company has made customary representations and warranties and has agreed to indemnify Craig-Hallum against certain liabilities.
On January 26, 2024, Cardio Diagnostics Holdings, Inc. entered into a Sales Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell up to $17 million in shares of its common stock at its discretion. The sales will be conducted as an 'at the market' offering under the company's effective Registration Statement, which was declared effective by the SEC on February 1, 2024. The company has the flexibility to determine the parameters of the share sales, including the number, timing, and minimum price of shares to be sold. Cardio Diagnostics Holdings will pay Craig-Hallum a 2.5% commission on the gross proceeds from the sales and will cover certain legal costs associated with the agreement. The offering will end when the total sales reach $17 million or upon termination of the Sales Agreement by either party. The net proceeds are intended for general corporate purposes. The company has made customary representations and warranties and has agreed to indemnify Craig-Hallum against certain liabilities.
2024年1月26日，Cardio Diagnostics Holdings, Inc.与Craig-Hallum Capital Group LLC签订了销售协议，允许该公司自行决定出售高达1700万美元的普通股。根据该公司的有效注册声明，此次销售将作为 “在市场上发行” 进行，该声明已由美国证券交易委员会于2024年2月1日宣布生效。公司可以灵活地确定股票销售的参数，包括出售股票的数量、时间和最低价格。Cardio Diagnostics Holdings将根据销售总收益向Craig-Hallum支付2.5％的佣金，并将支付与该协议相关的某些法律费用。当总销售额达到1700万美元或任何一方终止销售协议时，此次发行将结束。净收益用于一般公司用途。该公司已作出惯常陈述和保证，并同意向Craig-Hallum赔偿某些责任。
2024年1月26日，Cardio Diagnostics Holdings, Inc.与Craig-Hallum Capital Group LLC签订了销售协议，允许该公司自行决定出售高达1700万美元的普通股。根据该公司的有效注册声明，此次销售将作为 “在市场上发行” 进行，该声明已由美国证券交易委员会于2024年2月1日宣布生效。公司可以灵活地确定股票销售的参数，包括出售股票的数量、时间和最低价格。Cardio Diagnostics Holdings将根据销售总收益向Craig-Hallum支付2.5％的佣金，并将支付与该协议相关的某些法律费用。当总销售额达到1700万美元或任何一方终止销售协议时，此次发行将结束。净收益用于一般公司用途。该公司已作出惯常陈述和保证，并同意向Craig-Hallum赔偿某些责任。
有用
没用